AGREEMENT TO PROVIDE CONSULTING SERVICES. Effective Date: March 9, 2012Consulting Agreement • March 15th, 2012 • International Stem Cell CORP • Pharmaceutical preparations • California
Contract Type FiledMarch 15th, 2012 Company Industry JurisdictionInternational Stem Cell Corporation, a Delaware corporation (“the Company”), and Jeffrey Janus (hereafter referred to as “Consultant”), in consideration of the mutual promises made herein, agree as follows. This document may be referred to herein as “the Agreement or “this Agreement”
CONSULTATION CONTRACTConsultation Contract • March 15th, 2012 • International Stem Cell CORP • Pharmaceutical preparations • California
Contract Type FiledMarch 15th, 2012 Company Industry JurisdictionInternational Stem Cell Corporation, a Delaware corporation (“the Company”), and Kenneth C. Aldrich (hereafter referred to as “Consultant”), in consideration of the mutual promises made herein, agree as follows.
March 9, 2012Management Rights Agreement • March 15th, 2012 • International Stem Cell CORP • Pharmaceutical preparations
Contract Type FiledMarch 15th, 2012 Company IndustryThis letter will confirm our agreement that pursuant to and effective as of the purchase by AR Partners, LLC (“Investor”) of 5,000,000 shares of Series G Preferred Stock of International Stem Cell Corporation (“Company”), the Investor shall be entitled to the following contractual management rights:
SERIES G CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENTSeries G Convertible Preferred Stock Purchase Agreement • March 15th, 2012 • International Stem Cell CORP • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 15th, 2012 Company Industry JurisdictionTHIS SERIES G CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the Ninth day of March 2012 by and between International Stem Cell Corporation, a Delaware corporation (the “Company”) and AR Partners, LLC, a Delaware limited liability company (the “Purchaser”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 15th, 2012 • International Stem Cell CORP • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 15th, 2012 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 9th day of March 2012, by and among International Stem Cell Corporation, a Delaware corporation (the “Company”), AR Partners, LLC, a Delaware limited liability company, (the “Series G Investor”) and each of the investors listed on Schedule A of the Investors’ Rights Agreement made as of December 30, 2008 (each a “Series D Investor” and together with the Series G Investor, each an “Investor” as set forth on Schedule A hereto)